The HELX ETF invests in companies it identifies as relevant to advances in genomic analysis, gene editing, molecular diagnostics, and personalized medicine. Rather than passively tracking a specific index, it uses an active strategy, with the portfolio management team selecting holdings based on fundamental analysis.

It is well-suited for investors who are interested in the long-term growth potential of the genomic-technology and healthcare-innovation theme and who can tolerate the elevated volatility that comes with industry concentration.

It is an actively managed ETF run by Franklin Templeton.

The portfolio is built around companies that may benefit from advances in genomic technology. It covers related areas such as diagnostics, therapy development, research tools, pharmaceuticals, and agricultural applications, and reflects the managers' judgment on each company's business model and evolving technology landscape.

• Thematic screening across the genomic-technology value chain
• Stock selection through fundamental analysis rather than index replication

Assets under management (AUM) stand at $31.2M, and the total expense ratio is 0.50% annually.

A genomic-themed ETF can be more heavily influenced by individual holdings and sector-specific factors than a broad-market ETF. Bid-ask spreads and trading volume should be checked before placing orders, and the role of thematic exposure within your overall asset allocation should be reviewed at the same time.

Genomic and biotechnology stocks respond sensitively to clinical-trial results, regulatory decisions, R&D outcomes, and shifts in growth expectations. The performance of the HELX ETF is likewise shaped by these factors, and price swings can widen when long-term technology-adoption expectations intersect with short-term earnings uncertainty.

Fund flows into thematic healthcare products can vary with risk appetite, interest rates, drug-development news, and the regulatory environment. Because the HELX ETF is structured around a focus on genomic technology, it may be more sensitive to research developments in the industry and shifts in investor sentiment than to broader market flows.

The active, focused selection structure centered on the genomic-technology theme is a strength, while industry and stock concentration can amplify volatility.

In the comparison table, the DRAM ETF is classified as a memory-theme product, the SECT ETF focuses on sector rotation, the AVRE ETF on real estate, the VOLT ETF on electrification, and the CANC ETF on oncology. These ETFs differ from the HELX ETF in expense ratio, assets under management, and investment theme, serving less as direct substitutes than as benchmarks for comparing distinct themes. When reviewing genomic-technology exposure, it is advisable to also examine the distribution policy, trading conditions, and the degree of industry overlap.

When evaluating the HELX ETF, investors should review not only the growth expectations of the genomic theme but also the costs, trading conditions, portfolio concentration, and distribution policy. Top positions in the official holdings list include stocks such as GH, NTRA, KRYS, ADPT, and LGND, which are tied to genomic analysis and diagnostics, as well as therapy development.

Checklist	What to Confirm	Current Status
Total Expense Ratio	Check how costs compound on long-term holding returns	Disclosed figures need verification
Trading Conditions	Review trading volume and bid-ask spreads before placing orders	Verification needed
Theme Concentration	Confirm the level of healthcare and genomic-technology exposure	Concentration review needed
Distribution Policy	Confirm the distribution structure and tax treatment in advance	Annual distribution

Industry concentration and a non-diversified structure mean that changes in individual companies' clinical, regulatory, and competitive environments can be heavily reflected in the fund's value. Foreign securities, currency fluctuations, and market-trading conditions can also affect returns and transaction prices, so it is important to clearly delineate the role of this product relative to broad-market ETFs.

The HELX ETF is an active thematic product designed for investors seeking exposure to advances in genomic technology. However, unlike broad-market ETFs, it can be heavily influenced by industry concentration, R&D and regulatory variables, and individual stock-selection decisions, so it is advisable to confirm your investment objective and volatility tolerance before taking a position.

Reading alone isn't enough, is it?

Make your own call with Franklin Genomic Advancements ETF real-time data →

Briefs · earnings · signals, first Subscribe

Disclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.

This article reflects information as of August 17, 2026.

US STOCK TODAY Editorial Team

Every figure is calculated directly from filings and market data. How we work

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →